NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR
INDIRECTLY, IN OR INTO, THE UNITED STATES
OF AMERICA, CANADA,
NEW ZEALAND, SOUTH AFRICA, JAPAN, AUSTRALIA, SOUTH
KOREA, HONG KONG,
SWITZERLAND, SINGAPORE OR ANY OTHER JURISDICTION IN WHICH
THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR
REQUIRE REGISTRATION OR ANY OTHER MEASURE.
STOCKHOLM, Jan. 11, 2021 /PRNewswire/ -- Today is the
first day of the subscription period in Alligator Bioscience AB
(publ)'s ("Alligator" or the "Company") rights issue of shares
which was resolved upon by the Board of Directors on December 15, 2020 pursuant to the authorization
from the Annual General Meeting on May 5,
2020 (the "Rights Issue"). The general public also has the
opportunity to subscribe for shares in the Rights Issue.
To ensure continued successful development in accordance with
the Company's business plan and strategy, the Board of Directors of
Alligator has resolved to carry out the Rights Issue of
approximately SEK 86 million before
issue costs. The expected net proceeds from the Rights Issue will
be used to initiate and conduct Phase II studies for mitazalimab
and to complete phase I study and initiate preparatory work on
Phase II study for ATOR-1017. The Rights Issue is secured to 100
per cent by subscription undertakings and guarantee
commitments.
For complete information on the Rights Issue, please see the
prospectus (the "Prospectus"), which has been prepared by
the Board of Directors in connection with the Rights Issue.
Comment from Alligator's CEO, Per
Norlén
"With the capital injection from the rights issue, we secure the
start of important efficacy studies for our focus projects
mitazalimab and ATOR-1017. Just before year-end, we submitted a CTA
for mitazalimab, an application to start Phase II in pancreatic
cancer. For ATOR-1017, we plan to start Phase II
studies in the second half of 2021, with gastric cancer as a
prioritized indication. Based on strong data from preclinical
models and clinical Phase I, we see great opportunities for both
mitazalimab and ATOR-1017 to successfully treat patients with these
cancers."- Per Norlén, CEO of Alligator
The Rights Issue
The Rights Issue comprises a maximum of 14,277,723 shares. The
Rights Issue takes place with priority for those who were
registered as shareholders in the Company on the record date,
January 5, 2021. One (1) existing
share in the Company entitles to one (1) subscription right. Five
(5) subscription rights entitle to subscribe for one (1) new
share.
Timeline for the Rights
Issue
- January 11 - January 21, 2021 -
Trading in subscription
rights
- January 11 - January 25, 2021 -
Subscription
period
- January 11, 2021 - Until the
Rights Issue has been registered by the Swedish Companies
Registration Office - Trading in paid-up subscribed shares
(Sw.
"BTA")
- January 28, 2021 - Estimated
publication of outcome of Rights Issue
Investor presentations
The Company will be presenting at Redeye Fight Cancer Seminar on
January 21, 2021. Additional investor
presentations may be arranged during the subscription period.
Invitations will be presented on Alligator's and Redeye AB's
respective websites.
Prospectus
The Prospectus, containing complete terms and conditions, is
available on the Company's, Aktieinvest FK AB's and Redeye AB's
respective websites (www.alligatorbioscience.com,
www.aktieinvest.se and www.redeye.se). The Prospectus is also
available on the Swedish Financial Supervisory Authority's website
(www.fi.se). Subscription forms are available on the Company's and
Redeye AB's respective websites. Subscription forms can also be
obtained by contacting Aktieinvest FK AB on telephone number
08-5065 1795.
Advisers
Redeye AB acts as financial adviser, Setterwalls Advokatbyrå AB
acts as legal adviser and Aktieinvest FK AB acts as issuing agent
in connection with the Rights Issue.
For more information, please contact:
Per Norlén, CEO
Phone: 046-540 82 00
E-mail: per.norlen@alligatorbioscience.com
or
Cecilia Hofvander, Director Investor
Relations & Communications
Phone: 046-540 82 06
E-mail: cecilia.hofvander@alligatorbioscience.com
This information was submitted for publication, through the
agency of the contact persons set out above, at 8:30 a.m. CET on January
11, 2021.
About Alligator Bioscience AB
Alligator Bioscience AB is a clinical-stage biotechnology company
developing tumor-directed immuno-oncology antibody drugs.
Alligator's pipeline includes the two key assets ATOR-1017 and
mitazalimab. Furthermore, there are two partnered assets:
ALG.APV-527 in co-development with Aptevo Therapeutics Inc. and
AC101 in clinical development by Shanghai Henlius Biotech Inc. In
addition, the company has developed a novel concept for more
patient-specific immunotherapy: Neo-X-Prime. Alligator's shares are
listed on Nasdaq Stockholm (ATORX). The Company is headquartered in
Lund, Sweden. For more
information, please visit http://www.alligatorbioscience.com.
IMPORTANT INFORMATION
The information in this press release does not contain or
constitute an offer to acquire, subscribe or otherwise trade in
shares or other securities in Alligator. No action has been taken
and measures will not be taken to permit a public offering in any
jurisdictions other than Sweden.
Any invitation to the persons concerned to subscribe for shares in
Alligator will only be made through the Prospectus published by the
Company on December 30, 2020. The
Prospectus has been approved and registered by the Swedish
Financial Supervisory Authority and has been published on
http://www.alligatorbioscience.com. The approval of the Prospectus
by the Swedish Financial Supervisory Authority shall not be
regarded as an approval of the shares or any other securities. This
release is however not a prospectus in accordance to the definition
in the Prospectus Regulation (EU) 2017/1129 ("Prospectus
Regulation") and this announcement does not identify or
suggest, or purport to identify or suggest, the risks (direct or
indirect) that may be associated with an investment in shares or
other securities in Alligator. In order for investors to
fully understand the potential risks and benefits associated with a
decision to participate in the Rights Issue, any investment
decision should only be made based on the information in the
Prospectus. Thus, investors are encouraged to review the Prospectus
in its entirety. In accordance with article 2 k of the Prospectus Regulation this press
release constitutes an advertisement.
The information in this press release may not be released,
distributed or published, directly or indirectly, in or into
the United States of America,
Canada, New Zealand, South
Africa, Japan, Australia, South
Korea, Hong Kong,
Switzerland, Singapore or any other jurisdiction in which
such action would be unlawful or would require registration or any
other measures than those required by Swedish law. Actions in
violation of these restrictions may constitute a violation of
applicable securities laws. No shares or other securities in
Alligator have been registered, and no shares or other securities
will be registered, under the United States Securities Act of 1933,
as amended (the "Securities Act") or the securities
legislation of any state or other jurisdiction in the United States and no shares or other
securities may be offered, sold or otherwise transferred, directly
or indirectly, in or into the United
States, except under an available exemption from, or in a
transaction not subject to, the registration requirements under the
Securities Act and in compliance with the securities legislation in
the relevant state or any other jurisdiction of the United States.
Within the European Economic Area ("EEA"), no public
offering of Securities is made in other countries than Sweden. In other member states of the EU, such
an offering of Securities may only be made in accordance with the
Prospectus Regulation (EU) 2017/1129. In other member states of the
EEA which have implemented the Prospectus Regulation in its
national legislation, any offer of Securities may only be made in
accordance with an applicable exemption in the Prospectus
Regulation and/or in accordance with an applicable exemption under
a relevant national implementation measure. In other member states
of the EEA which have not implemented the Prospectus Regulation in
its national legislation, any offer of Securities may only be made
in accordance with an applicable exemption under national law.
This communication is only being distributed to and is only
directed at persons in the United
Kingdom that are (i) investment professionals falling within
Article 19(5) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005, as amended (the "Order")
or (ii) high net worth entities, and other persons to whom this
announcement may lawfully be communicated, falling within Article
49(2)(a) to (d) of the Order (all such persons together being
referred to as "Relevant Persons"). This communication must
not be acted on or relied on by persons who are not Relevant
Persons. Any investment or investment activity to which this
communication relates is available only to Relevant Persons and
will be engaged in only with Relevant Persons. Persons distributing
this communication must satisfy themselves that it is lawful to do
so.
This press release may contain forward-looking statements which
reflect the Company's current view on future events and financial
and operational development. Words such as "intend", "expect",
"anticipate", "may", "believe", "plan", "estimate" and other
expressions which imply indications or predictions of future
development or trends, and which are not based on historical facts,
are intended to identify forward-looking statements.
Forward-looking statements inherently involve both known and
unknown risks and uncertainties as they depend on future events and
circumstances. Forward-looking statements do not guarantee future
results or development and the actual outcome could differ
materially from the forward-looking statements.
The English text is an unofficial translation of the original
Swedish text. In case of any discrepancies between the Swedish text
and the English translation, the Swedish text shall prevail.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/alligator-bioscience/r/the-subscription-period-in-alligator-bioscience-s-rights-issue-commences-today,c3265794
The following files are available for download:
https://mb.cision.com/Main/12681/3265794/1357518.pdf
|
The subscription
period in Alligator Bioscience's rights issue commences
today
|